BNTC - Benitec Biopharma Limited
| Previous Close | 1.7700 |
| Open | 1.7900 |
| Bid | 0.0100 x 1000 |
| Ask | 2.4000 x 3100 |
| Day's Range | 1.7000 - 1.7900 |
| 52 Week Range | 1.0100 - 4.9000 |
| Volume | 1,212 |
| Avg. Volume | 6,875 |
| Market Cap | 21.782M |
| Beta (3Y Monthly) | 2.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- Simply Wall St.•14 days ago
Should Benitec Biopharma Limited (ASX:BLT) Be Your Next Stock Pick?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! As an investor, I look for investments which does not compromise one fundamental factor for...
- Simply Wall St.•3 months ago
Introducing Benitec Biopharma, The Stock That Tanked 92%
This month, we saw the Benitec Biopharma Limited (ASX:BLT) up an impressive 48%. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. In fact, theRead More...
- Simply Wall St.•4 months ago
Have Insiders Been Buying Benitec Biopharma Limited (ASX:BLT) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- PR Newswire•5 months ago
Benitec Provides Update on BB-401 Cancer Treatment Program
SYDNEY and HAYWARD, Calif. , Dec. 21, 2018 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) (the "Company"), a clinical-stage biotechnology company developing novel genetic medicines ...
- Simply Wall St.•6 months ago
Is Benitec Biopharma Limited’s (ASX:BLT) Balance Sheet A Threat To Its Future?
The direct benefit for Benitec Biopharma Limited (ASX:BLT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
- GlobeNewswire•6 months ago
Detailed Research: Economic Perspectives on Knight-Swift Transportation, Benitec Biopharma, Eastern, Kiniksa Pharmaceuticals, Qualstar, and Nomura Holdings Inc ADR — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•8 months ago
Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor
SYDNEY , Sept. 19, 2018 /PRNewswire/ -- Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a clinical-stage biotechnology company developing ...
- Motley Fool•10 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these hot biotech stocks get even hotter?
- Zacks•10 months ago
Axovant, Benitec Gain on Licensing Deal for Gene Therapy
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
- ACCESSWIRE•10 months ago
Today's Research Reports on Stocks to Watch: Benitec Biopharma and Pfizer
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Shares of Pfizer may have ended up flat yesterday but it wasn't the greatest news day for the pharmaceutical giant. President Trump took to Twitter to raise his concerns on the company as well as other drug makers for recently increasing prices. Shares of Benitec Biopharma was a big winner and even hit a new high after announcing a licensing agreement with Axovant.
- ACCESSWIRE•10 months ago
New Catalysts Could Send This $3 Medical Device Stock to $9
New entrant Biotricity (BTCY) is jumping into the same market with a potentially superior product and under-appreciated market valuation. BTCY expects to be prepared with two more products in the next 6-9 months, and they could all be on the market by the end of 2019. NEW YORK, NY / ACCESSWIRE / July 10, 2018 / With their latest investor update, Biotricity Inc. (BTCY) just dropped a major hint that most investors have been missing so far... key product updates are coming later this year.
Market Realist•10 months agoAxovant and Benitec Biopharma Up on Gene Therapy Development Deal
Axovant and Benitec Biopharma Rise on Gene Therapy Licensing DealAxovant and Benitec Biopharma enter into a licensing deal
- TheStreet.com•10 months ago
Axovant, Benetic Jump on Agreement to Develop Gene Therapy for MD
Shares of the biopharmaceutical company rose 5% in early morning trading Monday after it announced it had bought the rights to a new gene therapy treatment designed for a rare form of muscular dystrophy from Benitec Biopharma Ltd. Axovant rose 12 cents -- or 5% -- to $2.68 a share on news of the deal while Benitec skyrocketed $1.52 -- or 67.8% --$3.76. The two companies also entered into a research collaboration to develop five more treatments meant to target neurological disorders.
- PR Newswire•10 months ago
Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant
- Benitec to receive upfront cash payment of US$10 million with additional cash payments totalling US$17.5 million (a total of US$27.5M ) upon completion of near-term milestones for BB-301, now named AXO-AAV-OPMD ...
- PR Newswire•last year
Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update
NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today reported its consolidated financial results for the 2018 fiscal third quarter to 31 March 2018 (3Q FY18), and highlighted recent progress advancing its pipeline.
